Caris Life Sciences, Inc. (CAI)
NASDAQ · Healthcare
Caris Life Sciences, Inc. EBITDA 2023–2025
Caris Life Sciences, Inc. annual/quarterly ebitda history and growth rate from 2023 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Caris Life Sciences, Inc. ebitda for the quarter ending March 31, 2026 was 10.3 M, a 120.33% decrease year-over-year.
- Caris Life Sciences, Inc. ebitda for the twelve months ending March 31, 2026 was -14.6 M.
- Caris Life Sciences, Inc. annual ebitda for 2025 was 67.7 M, a 132.53% decrease from 2024.
- Caris Life Sciences, Inc. annual ebitda for 2024 was -208.2 M, a 23.04% decrease from 2023.
- Caris Life Sciences, Inc. annual ebitda for 2023 was -270.6 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Caris Life Sciences, Inc. EBITDA — FAQ
Caris Life Sciences, Inc. (CAI) ebitda over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CAI's ebitda history?
The chart and table above show Caris Life Sciences, Inc.'s ebitda by year and by quarter, including the growth rate.